Tempus AI, Inc. (TEM) Stock

Tempus AI, Inc. (TEM) is a Technology stock trading at $66.64 (as of 2026-08-20), with a market capitalization of $12.15M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Tempus AI, Inc. provides molecular and anatomic pathology testing, including next-generation sequencing, PCR profiling, and related diagnostic services for healthcare providers and life sciences customers. It also offers data and analytics platforms and services such as linked de-identified clinical datasets and tools for researchers, along with trial matching and algorithmic oncology testing.

Understand Tempus AI, Inc.: how it makes money

Tempus AI provides next-generation sequencing and other molecular and anatomic pathology testing to healthcare and life sciences customers, and it also monetizes de-identified linked clinical, molecular, and imaging data through Insights and analytical services to pharma and biotech.

The profit model is tied to recurring demand from biopharma and healthcare customers, it converts large remaining contract value into delivered work, and it monetizes the Insights data library through customer retention (Insights net revenue retention of 126%).

Business quality (Weak): Strong customer retention signal for Insights, but the company is still loss-making in the latest quarter (operating margin of -24.3%).

Bull case

  • Insights retention is above 100%, with Insights net revenue retention of 126%: This suggests the company can keep and expand monetization of its Insights license library and related analytics.
  • A large pipeline of contracted work remains to be delivered, with Remaining contract value yet to be delivered of 0.94 USD_B: This provides visibility into future delivery across its testing and services activities.

Bear case

  • The latest quarter shows material operating losses, with operating margin of -24.3%: Even with retention and contract visibility, the cost structure has not yet translated into profitability.
  • Revenue mix includes both Diagnostics and Data and applications, with overlap risks for how the business grows across testing versus data monetization: If data and applications growth does not keep pace with execution and delivery costs, losses may persist.
Valuation — source: SEC EDGAR (first-party)
Price$66.64
Market Cap$12.15M
Price / Book0.03
Price / Sales0.01
FCF Yield-2163.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.27B
Net Margin-19.3%
Revenue Growth (YoY)21.6%
EPS Growth (YoY)-112.0%
FCF Growth (YoY)-137.5%
Financial Health — source: SEC EDGAR
Altman Z-Score-0.86 (distress)
Valuation vs Sector & Industry
Sector P/E (Technology)33.9
Industry P/E (Business Services)30.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($605.77M)
Institutional Holders Tracked10
Congressional Trades (recent)2
Company
SectorTechnology
IndustryBusiness Services
CEOEric Lefkofsky
Employees2,400
CountryUS
IPO Date2024-06-14

Related Companies (Business model: SaaS / Subscription Software (Enterprise); 8 closest by market cap; US-domiciled)

  • Cardlytics, Inc. (CDLX)
  • Intelligent Protection Management Corp. (IPM)
  • System1, Inc. (SST)
  • Global Interactive Technologies, Inc. (GITS)
  • ZW Data Action Technologies Inc. (CNET)
  • TaoWeave, Inc. (TWAV)
  • Professional Diversity Network, Inc. (IPDN)
  • AiRWA Inc. (YYAI)
TEM earnings history · TEM institutional & insider holders · TEM KPIs & operating metrics · TEM financials · TEM investor presentations & press releases · TEM SEC filings · TEM peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.